vs
Perella Weinberg Partners（PWP）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Perella Weinberg Partners的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$219.2M vs $207.3M），Perella Weinberg Partners净利率更高（6.3% vs -62.0%，领先68.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -2.9%），Perella Weinberg Partners自由现金流更多（$30.5M vs $-100.8M），过去两年Perella Weinberg Partners的营收复合增速更高（46.5% vs 38.0%）
佩雷拉温伯格合伙公司是一家聚焦咨询业务的全球投资银行，核心为客户提供战略与财务领域的专业咨询服务，凭借深厚的行业经验和全球化资源网络，为各类企业的重要商业决策提供专业支持。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PWP vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.2M | $207.3M |
| 净利润 | $13.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 8.5% | -54.7% |
| 净利率 | 6.3% | -62.0% |
| 营收同比 | -2.9% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $219.2M | $207.3M | ||
| Q3 25 | $164.6M | $159.9M | ||
| Q2 25 | $155.3M | $166.5M | ||
| Q1 25 | $211.8M | $139.3M | ||
| Q4 24 | $225.7M | $164.6M | ||
| Q3 24 | $278.2M | $139.5M | ||
| Q2 24 | $272.0M | $147.0M | ||
| Q1 24 | $102.1M | $108.8M |
| Q4 25 | $13.8M | $-128.6M | ||
| Q3 25 | $6.0M | $-180.4M | ||
| Q2 25 | $2.7M | $-115.0M | ||
| Q1 25 | $17.3M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $16.4M | $-133.5M | ||
| Q2 24 | $-66.0M | $-131.6M | ||
| Q1 24 | $-35.8M | $-170.7M |
| Q4 25 | 8.5% | -54.7% | ||
| Q3 25 | 5.4% | -106.9% | ||
| Q2 25 | 5.8% | -64.8% | ||
| Q1 25 | 5.5% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 12.9% | -94.6% | ||
| Q2 24 | -30.2% | -79.1% | ||
| Q1 24 | -52.4% | -151.9% |
| Q4 25 | 6.3% | -62.0% | ||
| Q3 25 | 3.6% | -112.8% | ||
| Q2 25 | 1.8% | -69.0% | ||
| Q1 25 | 8.2% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 5.9% | -95.7% | ||
| Q2 24 | -24.3% | -89.5% | ||
| Q1 24 | -35.1% | -156.8% |
| Q4 25 | $0.11 | $-1.28 | ||
| Q3 25 | $0.08 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $0.24 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $0.24 | $-1.40 | ||
| Q2 24 | $-1.21 | $-1.52 | ||
| Q1 24 | $-0.91 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $255.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-127.4M | $-80.0M |
| 总资产 | $797.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $255.9M | $421.0M | ||
| Q3 25 | $185.5M | $202.5M | ||
| Q2 25 | $145.0M | $176.3M | ||
| Q1 25 | $111.2M | $127.1M | ||
| Q4 24 | $407.4M | $174.0M | ||
| Q3 24 | $335.1M | $150.6M | ||
| Q2 24 | $185.3M | $480.7M | ||
| Q1 24 | $156.7M | $112.3M |
| Q4 25 | $-127.4M | $-80.0M | ||
| Q3 25 | $-302.4M | $9.2M | ||
| Q2 25 | $-318.4M | $151.3M | ||
| Q1 25 | $-323.1M | $144.2M | ||
| Q4 24 | $-421.4M | $255.0M | ||
| Q3 24 | $-360.8M | $346.8M | ||
| Q2 24 | $-283.0M | $432.4M | ||
| Q1 24 | $161.9M | $140.3M |
| Q4 25 | $797.6M | $1.5B | ||
| Q3 25 | $650.2M | $1.2B | ||
| Q2 25 | $606.7M | $1.3B | ||
| Q1 25 | $570.5M | $1.3B | ||
| Q4 24 | $876.8M | $1.5B | ||
| Q3 24 | $810.9M | $1.5B | ||
| Q2 24 | $645.5M | $1.6B | ||
| Q1 24 | $583.6M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $30.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 13.9% | -48.6% |
| 资本支出强度资本支出/营收 | 2.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.52× | — |
| 过去12个月自由现金流最近4个季度 | $-34.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $34.8M | $-99.8M | ||
| Q3 25 | $59.2M | $-91.4M | ||
| Q2 25 | $56.1M | $-108.3M | ||
| Q1 25 | $-176.5M | $-166.5M | ||
| Q4 24 | $223.4M | $-79.3M | ||
| Q3 24 | $200.3M | $-67.0M | ||
| Q2 24 | $90.0M | $-77.0M | ||
| Q1 24 | $-206.3M | $-190.7M |
| Q4 25 | $30.5M | $-100.8M | ||
| Q3 25 | $57.6M | $-92.7M | ||
| Q2 25 | $55.3M | $-110.7M | ||
| Q1 25 | $-177.6M | $-167.8M | ||
| Q4 24 | $207.0M | $-79.5M | ||
| Q3 24 | $199.3M | $-68.6M | ||
| Q2 24 | $83.7M | $-79.0M | ||
| Q1 24 | $-214.8M | $-193.9M |
| Q4 25 | 13.9% | -48.6% | ||
| Q3 25 | 35.0% | -58.0% | ||
| Q2 25 | 35.6% | -66.5% | ||
| Q1 25 | -83.8% | -120.5% | ||
| Q4 24 | 91.7% | -48.3% | ||
| Q3 24 | 71.6% | -49.2% | ||
| Q2 24 | 30.8% | -53.7% | ||
| Q1 24 | -210.3% | -178.2% |
| Q4 25 | 2.0% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 7.3% | 0.1% | ||
| Q3 24 | 0.4% | 1.2% | ||
| Q2 24 | 2.3% | 1.4% | ||
| Q1 24 | 8.3% | 3.0% |
| Q4 25 | 2.52× | — | ||
| Q3 25 | 9.85× | — | ||
| Q2 25 | 20.50× | — | ||
| Q1 25 | -10.18× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.23× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PWP
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
